Tharimmune, Inc. (NASDAQ:THAR – Get Free Report) was the target of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 36,300 shares, an increase of 38.0% from the February 13th total of 26,300 shares. Currently, 1.9% of the shares of the stock are sold short. Based on an average trading volume of 98,300 shares, the short-interest ratio is currently 0.4 days.
Wall Street Analyst Weigh In
THAR has been the topic of a number of research analyst reports. Rodman & Renshaw initiated coverage on Tharimmune in a research report on Friday, December 6th. They set a “buy” rating and a $17.00 price target on the stock. RODMAN&RENSHAW upgraded Tharimmune to a “strong-buy” rating in a research report on Friday, December 6th.
Get Our Latest Analysis on Tharimmune
Tharimmune Stock Performance
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Tharimmune stock. Curi RMB Capital LLC acquired a new position in shares of Tharimmune, Inc. (NASDAQ:THAR – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned approximately 2.06% of Tharimmune as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 1.16% of the company’s stock.
About Tharimmune
Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).
See Also
- Five stocks we like better than Tharimmune
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- How to Build the Ultimate Everything ETF Portfolio
- How to Capture the Benefits of Dividend Increases
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Stock Splits, Do They Really Impact Investors?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Tharimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tharimmune and related companies with MarketBeat.com's FREE daily email newsletter.